Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-01, Stock:NVS, The news for the past five days is as follows:
2018-01-25: NEWS1: GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017.NEWS2: Biogen Revenue Tops As Spinraza, MS Drugs Deliver Upside.NEWS3: Biogen Revenue Tops As Spinraza, MS Drugs Deliver Upside.NEWS4: Celgene Reverses In Fourth Quarter As Otezla Sales Rebound.NEWS5: Celgene Reverses In Fourth Quarter As Otezla Sales Rebound.NEWS6: What Analysts Recommend for GlaxoSmithKline in January 2018.NEWS7: Taking Stock of Radius Health’s Licensing Agreements.NEWS8: Trump speaks with leaders from Total, Novartis and others....NEWS9: A Strong Pipeline of Drugs Bodes Well for Radius Health.NEWS10: European ADRs Move Higher in Thursday Trading.NEWS11: European ADRs Move Higher in Thursday Trading.NEWS12: Analysts’ Ratings for Radius Health and Its Peers in January.NEWS13: How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?.NEWS14: Analysts’ Estimates for Pfizer’s 4Q17 Earnings.NEWS15: Tasigna Could Boost Novartis’s Revenue Growth in 2018.NEWS16: Novartis Receives 2 Breakthrough Therapy Designations in January.NEWS17: The Swiss Stock Market Pulled Back After ECB Announcement.NEWS18: The Swiss Stock Market Pulled Back After ECB Announcement.NEWS19: Spark licenses blindness gene therapy rights outside U.S. to Novartis.
2018-01-26: NEWS1: Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors.NEWS2: Stocks With Rising Relative Strength: Novartis.NEWS3: Stocks With Rising Relative Strength: Novartis.NEWS4: Novartis Gets Spark Therapeutics' Luxterna License Outside US.NEWS5: Novartis Gets Spark Therapeutics' Luxterna License Outside US.NEWS6: Anoro Ellipta May Boost GlaxoSmithKline’s Respiratory Franchise Revenues.NEWS7: Novartis Gets Spark Therapeutics&apos; Luxterna License Outside US.NEWS8: GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment.NEWS9: What to Expect for Novartis’s Subsidiary Alcon in 2018.NEWS10: GlaxoSmithKline Has Developed a Broad Respiratory Portfolio.NEWS11: Taking Stock of Radius Health’s Financial Performance.NEWS12: How Is Novartis’s Subsidiary Sandoz Positioned for 2018?.NEWS13: The Swiss Stock Market Recovered Some Lost Ground.NEWS14: The Swiss Stock Market Recovered Some Lost Ground.
2018-01-29: NEWS1: Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors.NEWS2: Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors.NEWS3: Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion.NEWS4: Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion.NEWS5: Novartis&apos; Lutathera Gets FDA Approval for Pancreatic Tumors.NEWS6: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS7: Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM.NEWS8: Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ.NEWS9: Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ.NEWS10: Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ.NEWS11: The Swiss Stock Market Pulled Back As Investors Turn Cautious.NEWS12: The Swiss Stock Market Pulled Back As Investors Turn Cautious.
2018-01-30: NEWS1: Nucala May Be a Game-Changing Product in Respiratory Segment.NEWS2: Here's Why Momenta Pharmaceuticals, Inc. Jumped 12% Today.NEWS3: Here's Why Momenta Pharmaceuticals, Inc. Jumped 12% Today.NEWS4: An In-Depth Look at Array BioPharma’s Pipeline of Drugs.NEWS5: This Could Significantly Drive Gilead’s Revenue Growth in 2018.NEWS6: Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline.NEWS7: Analyst Ratings for Array BioPharma and Peers in January 2018.NEWS8: Johnson & Johnson’s Growth Rate for 4Q17.NEWS9: Roche Gets Breakthrough Therapy Designation For ASD Drug.NEWS10: Roche Gets Breakthrough Therapy Designation For ASD Drug.NEWS11: 3 Top Dividend Stocks With Yields Over 2%.NEWS12: 3 Top Dividend Stocks With Yields Over 2%.NEWS13: 3 Top Dividend Stocks With Yields Over 2%.NEWS14: The Swiss Stock Market Fell Further Due To Concerns Over US Bond Yields.NEWS15: The Swiss Stock Market Fell Further Due To Concerns Over US Bond Yields.
2018-01-31: NEWS1: A Key Update on Gilead Sciences’ ZUMA-3 Study.NEWS2: Array BioPharma’s ARRY-382 and ARRY-797.NEWS3: Wall Street Is More Optimistic about JNJ Stock after 4Q17 Results.NEWS4: Momenta Up on FDA's Amendment of McPherson Compliance Status.NEWS5: Momenta Up on FDA's Amendment of McPherson Compliance Status.NEWS6: The Best Arthritis Drug/Treatment Stocks on the Market Right Now.NEWS7: The Best Arthritis Drug/Treatment Stocks on the Market Right Now.NEWS8: What Else Could Drive Gilead’s Long-Term Growth?.NEWS9: The Swiss Stock Market Finished With A Substantial Loss.NEWS10: The Swiss Stock Market Finished With A Substantial Loss.NEWS11: Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX.NEWS12: Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX.

Answer: Rise